The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.
SMJ // Article
Original Article
Association between Maternal Buprenorphine Use and Fetal Head Circumference
Abstract
Objective: The objective of this study was to evaluate the effect of intrauterine buprenorphine exposure during pregnancy on fetal head circumference.Methods: This retrospective cohort study reviewed fetal ultrasound reports. Fetal anatomic surveys were typically performed at approximately 20 weeks’ gestation. Patients administered medication-assisted treatment (MAT) for opioid use disorder commonly had follow-up estimated fetal weight scans at approximately 32 weeks’ gestation due to risks of intrauterine growth restriction. A retrospective review of ultrasound reports for three groups of patients was performed. The very-low-dose (VLD) group (127 patients) was taking ≤2 mg buprenorphine in their third trimester; the traditional dose (TD) group (103 patients) received higher-dose MAT that was consistent with current recommendations. The control group, no buprenorphine use, included 212 patients. One-way analysis of variance and Tukey’s multiple comparison tests were used for statistical analysis. The effect size was measured using ω2.
Results: At the initial anatomy scan, no significant differences between groups were observed for head circumferences. By the third trimester growth scan, TD fetuses had significantly smaller head circumference percentiles compared with controls (P = 0.045). The estimated fetal weight percentile was lower in both buprenorphine groups compared with controls (VLD group vs controls, P = 0.021; TD group vs controls, P = 0.006), with TD fetuses showing the largest difference. Although TD head circumference percentiles were different from the controls, no significant differences were observed between the VLD group and either the TD group or controls for head circumference percentiles.
Conclusions: Previous studies have shown decreased head circumference in newborns in association with maternal MAT. This is the first study to provide ultrasound confirmation of decreased head circumference in fetuses exposed to buprenorphine. VLD buprenorphine may be associated with more favorable fetal growth measures compared with a TD. Interventions during pregnancy, including lowest effective dose treatment, may preserve fetal brain growth and improve long-term neurodevelopmental outcomes.
Posted in: Pregnancy0
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Suarez EA, Huybrechts KF, Straub L, et al. Buprenorphine versus methadone for opioid use disorder in pregnancy. N Engl J Med 2022;387:2033-2044.
2. American College of Obstetricians and Gynecologists. Committee opinion. Opioid use and opioid use disorder in pregnancy. https://www.acog.org/-/media/project/acog/acogorg/clinical/files/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy.pdf?rev%F0%90%80%80&%F0%90%80%80. Accessed August 12, 2025.
3. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363:2320-2331.
4. Nørgaard M, Nielsson MS, Heide-Jørgensen U. Birth and neonatal outcomes following opioid use in pregnancy: a Danish population-based study. Subst Abuse 2015;9( Suppl 2 ):5-11.
5. Asad M, Bonner-Reid FT, Aldoohan F, et al. Reviewing the impact of maternal opioid use disorder on fetal development and long-term pediatric health outcomes. Cureus 2024;16:e72192.
6. Abdelwahab M, Petrich M, Wang H, et al. Risk factors for preterm birth among gravid individuals receiving buprenorphine for opioid use disorder. Am J Obstet Gynecol MFM 2022;4:100582.
7. Suarez EA, Bateman BT, Straub L, et al. First trimester use of buprenorphine or methadone and the risk of congenital malformations. JAMA Intern Med 2024;184:242.
8. Leyenaar JK, Schaefer AP, Wasserman JR, et al. Infant mortality associated with prenatal opioid exposure. JAMA Pediatr 2021;175:706.
9. Fill MMA, Miller AM, Wilkinson RH, et al. Educational disabilities among children born with neonatal abstinence syndrome. Pediatrics 2018;142:e20180562.
10. Oei JL, Melhuish E, Uebel H, et al. Neonatal abstinence syndrome and high school performance. Pediatrics 2017;139:e20162651.
11. Hunt RW, Tzioumi D, Collins E, et al. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 2008;84:29-35.
12. Coulson CC, Lorencz E, Rittenhouse K, et al. Association of maternal buprenorphine or methadone dose with fetal growth indices and neonatal abstinence syndrome. Am J Perinatol 2021;38:028-036.
13. Towers CV, Hyatt BW, Visconti KC, et al. Neonatal head circumference in newborns with neonatal abstinence syndrome. Pediatrics 2019;143:e20180541.
14. Walhovd KB, Moe V, Slinning K, et al. Volumetric cerebral characteristics of children exposed to opiates and other substances in utero. NeuroImage 2007;36:1331-1344.
15. Caritis SN, Panigrahy A. Opioids affect the fetal brain: reframing the detoxification debate. Am J Obstet Gynecol 2019;221:602-608.
16. Yuan Q, Rubic M, Seah J, et al. Do maternal opioids reduce neonatal regional brain volumes? A pilot study. J Perinatol 2014;34:909-913.
17. O’Connor A, O’Brien L, Watson L. Implications of perinatal buprenorphine exposure on infant head circumference at birth. J Matern Fetal Neonatal Med 2021;34:318-322.
18. Kumar N, Rocha FG, Moustafa ASZ, et al. Impact of opioid maintenance treatment during pregnancy on neonatal birth weight and head circumference. J Neonatal-Perinat Med 2021;14:475-484.
19. Freire MBO, Slater R, Santos TM, et al. Head circumference and intelligence, schooling, employment, and income: a systematic review. BMC Pediatr 2024;24:709.
20. Suboxone sublingual film [package insert]. North Chesterfield, VA: Indivior; 2026.
21. Subutex Prescribing information. https://wwwaccessdata.fda.gov/drugsatfda_docs/label/2022/020732s027s028lbl.pdf. Accessed August 7, 2025.
22. Kirk RE. Practical significance: a concept whose time has come. Educ Psychol Meas 1996;56:746-759.
23. Nagaraj UD, Kline-Fath BM, Zhang B, et al. MRI findings in third-trimester opioid-exposed fetuses, with focus on brain measurements: a prospective multicenter case-control study. Am J Roentgenol 2023;220:418-427.
24. Sirnes E, Oltedal L, Bartsch H, et al. Brain morphology in school-aged children with prenatal opioid exposure: a structural MRI study. Early Hum Dev 2017;106-107:33-39.
25. Larson JJ, Graham DL, Singer LT, et al. Cognitive and behavioral impact on children exposed to opioids during pregnancy. Pediatrics 2019;144:e20190514.
26. Alexander C, Breuel K, Olsen M. High prevalence of buprenorphine in prenatal drug screens in an Appalachian city. South Med J 2020;113:111-115.
27. Shah D, Adelli R, Chroust A, et al. Outpatient tapering of buprenorphine in opioid use disorder pregnancies may improve neonatal outcomes. J Perinatol 2025;45:480-486.
28. FDA analysis of long-term trends in prescription opioid analgesic products: quantity, sales, and price trends. https://www.fda.gov/media/111695/download. Accessed August 7, 2025.
29. Rana D, McLeod AR, Gaston PK, et al. Assessing neonatal opioid withdrawal syndrome severity as a function of maternal buprenorphine dose and umbilical cord tissue concentrations. Ann Pharmacother 2023;57:892-898.
30. Patel N, O’Brien J, Cockerham C, et al. Weaning buprenorphine in pregnant patients #. J Matern Fetal Neonatal Med 2024;37:2337711.
31. Marc B, Marion D, Franç B, et al. Is buprenorphine maternal dose associated with neonatal opioid withdrawal syndrome severity? Am J Addict 2025;34:15-20.
